Inhaled aztreonam

Nature Reviews Drug Discovery

Volumn 9, Issue 5, 2010, Pages 357-358

  O'Sullivan, Brian P ^a   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATALUREN; AZTREONAM; CAYSTON; COLISTIN; PLACEBO; RESPIRATORY TRACT AGENT; TOBRAMYCIN; UNCLASSIFIED DRUG; VX 770; VX 809;

CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG RESPONSE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG INFECTION; NEBULIZATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SHORT SURVEY;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; AZTREONAM; CYSTIC FIBROSIS; DRUG DISCOVERY; HUMANS; LYSINE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 77951817843     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3170     Document Type: Short Survey

References (15)

1. O'Sullivan, B. P. & Freedman, S. D. Cystic fibrosis. Lancet 373, 1891-1904 (2009).
2. Geller, D. E. Aerosol antibiotics in cystic fibrosis. Respir. Care 54, 658-670 (2009)
3. Novartis. Prescribing information\Tobi. Novartis Pharmaceutical Corporation website [online], http://www.pharma.us.novartis.com/product/pi/pdf/ tobi. pdf (2010).
4. Sykes, R. B. et al. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic Gram-negative bacteria. Antimicrob. Agents Chemother. 21, 85-92 (1982).
5. Gibson, R. L. et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr. Pulmonol. 41, 656-665 (2006).
6. US Food and Drug Administration. FDA labelling information\Cayston. FDA website [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 050814lbl.pdf (2010).
7. Retsch-Bogart, G. Z. et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 135, 1223-1232 (2009).
8. Jensen, T. et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother.19, 831-838 (1987). (Pubitemid 17092071)
9. McCoy, K. S. et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med.178, 921-928 (2008).
10. Flume, P. A. et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 176, 957-969 (2007).
11. Smith, B. A. & Wood, B. L. Psychological factors affecting disease activity in children and adolescents with cystic fibrosis: medical adherence as a mediator. Curr. Opin. Pediatr.19, 553-558 (2007).
12. Ashlock, M. A. et al. A pipeline of therapies for cystic fibrosis. Semin. Respir. Crit. Care Med. 30, 611-626 (2009).
13. IMS MIDAS (IMS Health, 2009).
14. European Medicines Agency. Final assessment report for Cayston. International nonproprietary name: aztreonam. Procedure No. EMEA/H/C/000996. EMA website [online], http://www.ema.europa.eu/humandocs/PDFs/EPAR/cayston/H-996- en6.pdf (2009).
15. Wei, T., Deepak, S. & Nguyen, T. Equity research report. (Jefferies & Company Inc.; February 2010).